Clinical Trial Costs & Timelines — Latin America vs. US/EU — bioaccess®

Medically reviewed by Dr. Pedro Martinez-Clark, MD and Dr. William O'Neill, MD. Last reviewed: July 2026.

bioaccess® presents the following cost and timeline comparisons for clinical trials in Latin America versus the United States and European Union.

Cost Comparison: Latin America vs. US/EU

• Per-patient cost (FIH device study): LATAM $15,000–$35,000 vs. US/EU $40,000–$75,000 (US Phase I per-patient benchmarked ~$137,000)
• 10-patient FIH study (CRO fees): LATAM $300,000–$500,000 vs. US $750,000–$1,500,000
• 5-patient early feasibility study (EFS): LATAM $200,000–$300,000 vs. US $500,000–$750,000
• Ethics committee / IRB fees: LATAM $500–$3,000 vs. US/EU $5,000–$25,000
• Site startup: LATAM $15,000–$40,000 vs. US/EU $50,000–$150,000

Per-Patient Cost by Country

• Paraguay (DINAVISA): $10,000–$18,000 — lowest per-patient cost in LATAM
• Colombia (INVIMA): $15,000–$25,000 — approval in 4–6 weeks
• Mexico (COFEPRIS): $18,000–$30,000 — US-adjacent timezone, 130M+ population
• Brazil (ANVISA): $20,000–$35,000 — 210M+ population for FDA diversity
• Panama (MINSA/CNBI): $18,000–$30,000 — 3–5 week ethics, no MOH review
• El Salvador (DNM/CNEIS): $15,000–$28,000 — 30-day startup, dollarized economy

What Drives the 30–50% Cost Advantage

• Site and hospital fees 40–70% lower than US/EU academic medical centers
• Lower clinical labor costs (coordinators, sub-investigators, monitors) at ICH-E6 GCP competency
• Ethics-committee and submission fees of $500–$3,000 vs. $5,000–$25,000 in the US/EU
• Faster recruitment from large, treatment-naïve populations, reducing per-patient carrying cost

The cost advantage is structural, not a quality trade-off. Data is FDA-accepted under 21 CFR 812.28 (devices) and 21 CFR 312.120 (drugs and biologics) when studies meet ICH-E6 GCP standards.

Timeline Comparison

• Ethics Approval: US/EU 6–12 months vs. LATAM 4–8 weeks
• Regulatory Approval: US/EU 3–12 months vs. LATAM 1–3 months
• First Patient Enrolled: US/EU 12–18 months vs. LATAM 4–8 months
• Total Study Duration: US/EU 18–36 months vs. LATAM 8–18 months

Cost Breakdown (standard study)

• CRO professional services: ~$350,000 (1 site, 10 subjects, 24-month duration)
• Third-party costs: ~$50,000 (insurance, translations, IRB/EC and MOH submission fees, importation, travel)
• Hospital fees: $5,000–$50,000 depending on procedure complexity

Use the Cost Calculator · Request a Quote